Moderna Rg
MRNA
USD
STOCK MARKET:
NMS
Closed
 
...
Large gap with delayed quotes
Last quote
10/18/2025 - 02:00:00
Bid
10/17/2025 - 21:59:59
Bid
Volume
Ask
10/17/2025 - 21:59:59
Ask
Volume
26.01
-1.13 ( -4.16% )
25.99
20,200
26.00
27,500
More information
Analysis by TheScreener
14.10.2025
Evaluation Slightly negative  
Interest Strong  
Sensibility High  
Analysis date: 14.10.2025
Global Evaluation
  Slightly negative
The stock is classified in the slightly negative zone since 30.09.2025.
Interest
  Strong
Three stars since 03.10.2025.
Earnings Rev Trend
  0.10
 
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is positive since 03.10.2025 at a price of 28.49.
Evaluation
  Strongly overvalued
 
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
  Neutral
 
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 03.10.2025.
4wk Rel Perf
  10.74%
 
The four-week dividend-adjusted overperformance versus SP500 is 10.74%.
Sensibility
  High
High, no change over 1 year.
Bear Market Factor
  High
On average, the stock has a tendency to amplify the drops in the index by 1.73%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 5.25%.
Mkt Cap in $bn
  10.44
With a market capitalization >$8bn, MODERNA is considered a large-cap stock.
G/PE Ratio
  1.70
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
  -4.76
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
  8.11%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
  21
Over the last seven weeks, an average of 21 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  104
For 1% of index variation, the stock varies on average by 1.04%.
Correlation
  0.30
Stock movements are strongly independent of index variations.
Value at Risk
  13.89
The value at risk is estimated at USD 13.89. The risk is therefore 52.93%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  29.03.2019